Procalcitonin: A Severity Marker for Pre-Eclampsia?
DOI:
https://doi.org/10.12970/2311-1755.2014.02.01.4Keywords:
Procalcitonin, Pre-eclampsia, inflammation, marker.Abstract
Introduction: Pre-eclampsia is a common and potentially dangerous disorder of human pregnancy. The maternal syndrome of hypertension and proteinuria is part of a severe systemic inflammatory response that includes leukocyte and endothelial cell activation.
PCT is a polypeptide consisting of 116 aminoacids and is the precursor of calcitonin. Over the last decade, PCT has become increasingly popular as a novel marker of infection in the intensive care unit setting.
The aim of our study was to evaluate changes in serum levels of PCT in pregnancies complicated with mild pre-eclampsia or severe pre-eclampsia and further investigate the correlation with CRP.
Methods: Throughout the study period, 80 pregnant women complicated with mild preeclampsia, 80 pregnant women complicated with severe preeclampsia and 80 healthy pregnant women as a control group, giving a total of 240 pregnant women were enrolled into study.
Results: Both severe pre-eclampsia and mild pre-eclampsia groups showed significantly higher PCT values when compared with control healthy group (p<0.05). Also, severe pre-eclampsia group showed significantly higher PCT values when compared with mild pre-eclampsia group (p<0.05).
A statistically significant correlation was observed in between presence of pre-eclampsia and procalcitonin positivity (p<0.05). And also severity of pre-eclampsia has shown a statistically significant correlation with high values of procalcitonin (p<0.05).
Conclusion: Procalcitonin might be a diagnostic marker for investigating women especially with suspected severe preeclampsia.
References
Borzychowski AM, Sargent IL, Redman CWG. Inflammation and preeclampsia. Semin Fetal Neonatal Med 2006; 11: 309-16. http://dx.doi.org/10.1016/j.siny.2006.04.001
Maruna P, Nedelnikova R, Gurlich R. Physiology and genetics of procalcitonin. Physiol Res 2000; 49: 57-61.
Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341: 515-8. http://dx.doi.org/10.1016/0140-6736(93)90277-N
Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79: 1605-8.
Nijsten M, Olinga P, The TH, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med 2000; 28: 458-61. http://dx.doi.org/10.1097/00003246-200002000-00028
Oberhoffer M, Stonans I, Russwurm S, et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis related cytokines in vitro. J Lab Clin Med 1999; 134: 49-55. http://dx.doi.org/10.1016/S0022-2143(99)90053-7
Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39: 206-17. http://dx.doi.org/10.1086/421997
Castelli GP, Prognani C, Meisner M, Stuani A, Bellomi D, Sgarbi L. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care 2004; 8: 234-42. http://dx.doi.org/10.1186/cc2877
Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med 2003; 31: 1737-41. http://dx.doi.org/10.1097/01.CCM.0000063440.19188.ED
Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 2000; 26: 148-52. http://dx.doi.org/10.1007/s001340051134
Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006; 34: 1996-2003. http://dx.doi.org/10.1097/01.CCM.0000226413.54364.36
Marc E, Menager C, Moulin F, et al. Procalcitonin measurement for reducing antibiotic treatments during outbreak of viral meningitis in children. Arch Pediatr 2002; 9: 1-7.
Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use outcome in lower respiratory tract infections: cluster-randomized, single-blinded intervention trial. Lancet 2004; 363: 600-7. http://dx.doi.org/10.1016/S0140-6736(04)15591-8
Sandek A, Springer J, Habedank D, Brunkhorst FM, Anker SD. Procalcitonin-guided antibiotic treatment in heart failure. Lancet 2004; 363: 1555-6. http://dx.doi.org/10.1016/S0140-6736(04)16165-5
Oberhoffer M, Vogelsang H, Russwurm S, Hartung T, Reinhart K. Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med 1999; 37: 363-8. http://dx.doi.org/10.1515/CCLM.1999.060
Oczenski W, Fitzgerald RD, Schwarz S. Procalcitonin: a new parameter for the diagnosis of bacterial infection in the peri-operative period. Eur J Anaesthesiol 1998; 15: 202-9. http://dx.doi.org/10.1111/j.0265-0215.1998.00280.x
Luyt CE, Guerin V, Combes A, et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 48-53. http://dx.doi.org/10.1164/rccm.200406-746OC
Nylen ES, Whang KT, Snider RH, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 1998; 26: 1001-6. http://dx.doi.org/10.1097/00003246-199806000-00015
Schneider HG, Lam QT. Procalcitonin for the clinical laboratory: a review. Pathology 2007; 39: 383-90. http://dx.doi.org/10.1080/00313020701444564
Masse J, Giguere Y, Kharfi A, Girouard J, Forest JC. Pathophysiology and maternal biologic markers of preeclampsia. Endocrine 2002; 19: 113-25. http://dx.doi.org/10.1385/ENDO:19:1:113
Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 2001; 280: 193-206.
Bird IM, Zhang L, Magness RR. Possible mechanisms underlying pregnancy-induced changes in uterine artery endothelial function. Am J Physiol Regul Integr Comp Physiol 2003; 284: 245-58.
Hoffmann G, Totzke G, Seibel M, Smolny M, Wiedermann FJ. In vitro modulation of inducible nitric oxide synthase gene expression and nitric oxide synthesis by procalcitonin. Crit Care Med 2001; 29: 112-6. http://dx.doi.org/10.1097/00003246-200101000-00023
Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop preeclampsia. Lancet 2003; 361: 1511-7. http://dx.doi.org/10.1016/S0140-6736(03)13177-7
Kharb S, Gulati N, Singh V, Singh GP. Lipid peroxidation and vitamin E levels in preeclampsia. Gynecol Obstet Invest 1996; 46: 238-40. http://dx.doi.org/10.1159/000010041
Reinhart K, Bayer O, Brunkhorst F, Meisner M. Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 2002; 30(Suppl): 302-12. http://dx.doi.org/10.1097/00003246-200205001-00021
Whicher J, Bienvenu J, Monneret G. Procalcitonin as an acute phase marker. Ann Clin Biochem 2001; 38: 483-93. http://dx.doi.org/10.1177/000456320103800505
Montagnana M, Lippi G, Albiero A, et al. Procalcitonin values in preeclamptic women are related to severity of disease. Clin Chem Lab Med 2008; 46: 1050-1. http://dx.doi.org/10.1515/CCLM.2008.199
